Last updated: 1 April 2021 at 7:51pm EST

Rahul Kakkar Net Worth




The estimated Net Worth of Rahul Kakkar is at least 841 千$ dollars as of 17 July 2020. Rahul Kakkar owns over 14,000 units of Pandion Therapeutics stock worth over 840,700$ and over the last 4 years Rahul sold PAND stock worth over 0$.

Rahul Kakkar PAND stock SEC Form 4 insiders trading

Rahul has made over 1 trades of the Pandion Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Rahul bought 14,000 units of PAND stock worth 252,000$ on 17 July 2020.

The largest trade Rahul's ever made was buying 14,000 units of Pandion Therapeutics stock on 17 July 2020 worth over 252,000$. On average, Rahul trades about 4,667 units every 0 days since 2020. As of 17 July 2020 Rahul still owns at least 14,000 units of Pandion Therapeutics stock.

You can see the complete history of Rahul Kakkar stock trades at the bottom of the page.



What's Rahul Kakkar's mailing address?

Rahul's mailing address filed with the SEC is C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE, WATERTOWN, MA, 02472.

Insiders trading at Pandion Therapeutics

Over the last 4 years, insiders at Pandion Therapeutics have traded over 0$ worth of Pandion Therapeutics stock and bought 1,743,632 units worth 30,815,954$ . The most active insiders traders include Plc GskCapital Management, L.P.Kol...Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of 9,518,646$. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth 2,989,466$.



What does Pandion Therapeutics do?



What does Pandion Therapeutics's logo look like?

Pandion Therapeutics, Inc. logo

Complete history of Rahul Kakkar stock trades at Pandion Therapeutics

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
17 Jul 2020 Rahul Kakkar
Chief Executive Officer
購入する 14,000 18.00$ 252,000$
17 Jul 2020
14,000


Pandion Therapeutics executives and stock owners

Pandion Therapeutics executives and other stock owners filed with the SEC include: